

Recommendations from York and Scarborough Medicines Commissioning Committee April 2015

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Nalmefene (Selincro®)	Reduction of alcohol consumption in adult patients	North Yorkshire County Council position approved	Specialist prescribing/monitoring/support required	Alcohol specialist services prescribing only in accordance with specification. Not for primary care prescribing	Red - alcohol specialist service only.	Nil
Tocilizumab subcutaneous injection (RoActemra®)	Rheumatoid arthritis	Approved	Cost effectiveness compared with intravenous formulation.	Treatment option for rheumatoid arthritis patients in line with NICE TA 247.	Red	Savings will be achieved by avoidance of IV administration costs
Empagliflozin (Jardiance®)	Type 2 diabetes	Approved	NICE TA 336 recommends as a treatment option.	Option for dual or triple therapy	Green	Costs similar to other agents in the class
Rifaximin (Targaxan®)	Preventing episodes of overt hepatic encephalopathy in adults	Approved	NICE TA 337 recommends as a treatment option.	Reduction in recurrence of episodes of overt hepatic encephalopathy in adults	Amber – specialist initiation	Annual cost/patient £3,370. Local estimates suggest 20 patient per year (across York & Scarborough Trust) £67,400.

Rivaroxaban (Xarelto®)	Acute coronary syndrome	Approved	NICE TA 335 recommends as a treatment option.	With aspirin alone or with aspirin and clopidogrel for the prevention of atherothrombotic after an acute coronary syndrome.	Amber – specialist initiation as per product licence.	Additional acquisition costs are £766.50 per patient (for 12 months treatment).
Ferrous sulphate tablets	Prophylaxis/ treatment of iron deficiency	Approved	Drug shortage – formulary product substitution	In place of ferrous fumarate which is unavailable – drug shortage	Green	Costs additional 35p per 28 tablets
Ticagrelor (Brilique®)	Acute coronary syndrome	Approved	Formalisation of commissioning position.	Commissioned only in accordance with NICE TA236 for treatment up to 12 months after ACS.	Amber – specialist initiation	No additional costs incurred

Additional items

Medal ranking – oral nutritional supplements